The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: A meta-analysis

Zuo, Zhihua; Jiang, Yao; Zeng, Shanshui; Li, Yiqin; Fan, Jia; Guo, Yongcan; Tao, Hualin

doi:10.1016/j.prp.2020.153130

Cited by 15 publications

(10 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have further investigated predictive value of non-invasive molecular biomarkers, i.e., liquid biopsies such as circulating long-coding RNAs or microRNAs for CRC. Meta-analyses and systemic-reviews conclude, that they have high diagnostic and prognostic value for patients with CRC [20][21][22]. However, no RNA-based biomarkers have yet entered routine clinical practice.…”

Section: Mmrd/msi-hmentioning

confidence: 99%

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases

Czauderna¹,

Luley

Bubnoff

et al. 2021

IJMS

View full text Add to dashboard Cite

Liver metastases are the most common site of metastatic spread in colorectal cancer. Current treatment approaches involve effective systemic therapies in combination with surgical and/or interventional strategies. Multimodal strategies greatly improved clinical outcomes of patients with metastatic colorectal cancer over the last decades. Identification of predictive and prognostic biomarkers helped to comprehensively refine individual targeted treatment approaches and resulted in median overall survival rates of 30 months or longer. Current guidelines, thus, recommend treatment selection according to patients’ performance status, tumor localization and stage as well as the tumor’s molecular and genetic status. Here, we outline the latest developments in molecular decision-making for patients with upfront resectable, potentially or initially unresectable and non/never-resectable colorectal cancer liver metastases.

show abstract

Section: Mmrd/msi-hmentioning

confidence: 99%

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases

Czauderna¹,

Luley

Bubnoff

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Recently, Zuo et al conducted a meta-analysis investigating the diagnostic accuracy of single miRNAs in CRC patients ( 57 ). In this meta-analysis, including 33 articles published between 2009 and 2019, Zuo et al showed that the sensitivity, specificity, PLR, NLR, DOR, and AUC of overall miRNAs were 0.80, 0.80, 4.00, 0.26, 16, and 0.87, respectively, which were similar to this study’s results.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis

2022

View full text Add to dashboard Cite

BackgroundCirculating microRNAs (miRNA) have emerged as promising diagnostic biomarkers for several diseases, including cancer. However, the diagnostic accuracy of miRNA panels in colorectal cancer (CRC) remains inconsistent and there is still lack of meta-analyses to determine whether miRNA panels can serve as robust biomarkers for CRC diagnosis.MethodsThis study performed a systematic review and meta-analysis to evaluate the clinical utility of miRNA panels as potential biomarkers for the diagnosis of CRC. The investigation systematically searched PubMed, Medline, Web of Science, Cochrane Library, and Google Scholar (21-year span, between 2000 and 2021) to retrieve articles reporting the diagnostic role of miRNA panels in detecting CRC. Diagnostic meta-analysis of miRNA panels used diverse evaluation indicators, including sensitivity, specificity, Positive Likelihood Ratio (PLR), Negative Likelihood Ratio (NLR), Diagnostic Odds Ratio (DOR), and the area under the curve (AUC) values.ResultsAmong the 313 articles identified, 20 studies met the inclusion criteria. The pooled estimates of miRNA panels for the diagnosis of CRC were 0.85 (95% CI: 0.84–0.86), 0.79 (95% CI: 0.78–0.80), 4.06 (95% CI: 3.89–4.23), 0.20 (95% CI: 0.19–0.20), 22.50 (95% CI: 20.81–24.32) for sensitivity, specificity, PLR, NLR, and DOR, respectively. Moreover, the summary receiver operating characteristics (SROC) curve revealed an AUC value of 0.915 (95% CI: 0.914–0.916), suggesting an outstanding diagnostic accuracy for overall miRNA panels. Subgroup and meta-regression analyses demonstrated that miRNA panels have the highest diagnostic accuracy within serum samples, rather than in other sample-types – with a sensitivity, specificity, PLR, NLR, DOR, and AUC of 0.87, 0.86, 7.33, 0.13, 55.29, and 0.943, respectively. Sensitivity analysis revealed that DOR values did not differ markedly, which indicates that the meta-analysis had strong reliability. Furthermore, this study demonstrated no proof of publication bias for DOR values analyzed using Egger’s regression test (P > 0.05) and funnel plot. Interestingly, miR-15b, miR-21 and miR-31 presented the best diagnostic accuracy values for CRC with sensitivity, specificity, PLR, NLR, DOR, and AUC values of 0.95, 0.94, 17.19, 0.05, 324.81, and 0.948, respectively.ConclusionThis study’s findings indicated that miRNA panels, particularly serum-derived miRNA panels, can serve as powerful and promising biomarkers for early CRC screening.Systematic review registration[www.crd.york.ac.uk/prospero], identifier [CRD42021268172].

show abstract

“…A recent meta-analysis [69] encompassing 35 studies published from 2009 to 2019 and including 3258 CRC patients and 2683 healthy controls analyzed serum-derived miRNA panels. More precisely, it focused on multiple miRNA serum-derived panels (and not single-miRNA assays), demonstrating them as promising markers of early diagnosis of CRCs.…”

Section: Micrornas As a Diagnosis Biomarker In Crcsmentioning

confidence: 99%

The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer

Al‐Akhrass

Christou

2021

Cancers

View full text Add to dashboard Cite

MiRNAs have recently become a subject of great interest within cancers and especially colorectal cancers in diagnosis, prognosis, and therapy decisions; herein we review the current literature focusing on miRNAs in colorectal cancers, and we discuss future challenges to use this tool on a daily clinical basis. In liquid biopsies, miRNAs seem easily accessible and can give important information toward each step of the management of colorectal cancers. However, it is now necessary to highlight the most sensitive and specific miRNAs for each goal thanks to multicentric prospective studies. Conclusions: by their diversity and the feasibility of their use, miRNAs are getting part of the armamentarium of healthcare management of colorectal cancers.

show abstract

The value of microRNAs as the novel biomarkers for colorectal cancer diagnosis: A meta-analysis

Cited by 15 publications

References 73 publications

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases

Tailored Systemic Therapy for Colorectal Cancer Liver Metastases

MicroRNA panels as diagnostic biomarkers for colorectal cancer: A systematic review and meta-analysis

The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer

Contact Info

Product

Resources

About